Bicara Therapeutics Inc. Common Stock (BCAX) vs Cullinan Therapeutics, Inc. (CGEM)

A side-by-side comparison of Bicara Therapeutics Inc. Common Stock and Cullinan Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Bicara Therapeutics Inc. Common Stock logo
BCAX
Bicara Therapeutics Inc. Common Stock
$1.09B
$16.62HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Cullinan Therapeutics, Inc. logo
CGEM
Cullinan Therapeutics, Inc.
$1.06B
$17.21HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT

Total return — BCAX vs CGEM

growth of $100 · dividends reinvested · last 2y
BCAX -26.1% (-14.1%/yr)CGEM -9.0% (-4.6%/yr)CGEM compounded faster over this window
406080100120Start $10020252026$74$91
BCAX CGEM

BCAX vs CGEM: by the numbers

  • •BCAX is the larger company ($1.09B vs $1.06B market cap).

Metrics side by side

Valuation

MetricBCAXCGEM
P/B ratio2.333.29

Profitability

MetricBCAXCGEM
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-39.54%-63.62%
ROIC-42.98%-68.64%

Growth (annualized)

MetricBCAXCGEM
Total return CAGR (5Y)N/A-7.48%

Go deeper

Full BCAX analysisFull CGEM analysisInteractive comparison tool

Dig into the metrics

Bicara Therapeutics Inc. Common Stock ROECullinan Therapeutics ROEBicara Therapeutics Inc. Common Stock operating marginCullinan Therapeutics operating marginBicara Therapeutics Inc. Common Stock revenue growthCullinan Therapeutics revenue growthBicara Therapeutics Inc. Common Stock free cash flowCullinan Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.